Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential donor lymphocyte infusion and cytokine-induced killer cells after allogeneic stem cell transplantation
2008-003185-26Phase 2Active
- Sponsor
- Papa Giovanni XXIII Hospital
- Start
- Oct 2008
- Modality
- Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of unmodified CIK and donor lymphocytes in hematopoietic malignancies, sponsored by Papa Giovanni XXIII Hospital. Primary endpoint: Overall response rate. Started Oct 2008; status: active.
02
Drugs
unmodified CIKdonor lymphocytes
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on 2008-003185-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003185-26.